185 related articles for article (PubMed ID: 28336809)
1. Lectin, Galactoside-Binding Soluble 3 Binding Protein Promotes 17-N-Allylamino-17-demethoxygeldanamycin Resistance through PI3K/Akt Pathway in Lung Cancer Cell Line.
Woo JK; Jang JE; Kang JH; Seong JK; Yoon YS; Kim HC; Lee SJ; Oh SH
Mol Cancer Ther; 2017 Jul; 16(7):1355-1365. PubMed ID: 28336809
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of Xeroderma Pigmentosum Complementation Group C Expression by 17-Allylamino-17-Demethoxygeldanamycin Enhances Bevacizumab-Induced Cytotoxicity in Human Lung Cancer Cells.
Chen JC; Ko JC; Taso YC; Cheng HH; Chen TY; Yen TC; Lin YW
Pharmacology; 2021; 106(3-4):154-168. PubMed ID: 33202406
[TBL] [Abstract][Full Text] [Related]
3. LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis.
Piccolo E; Tinari N; Semeraro D; Traini S; Fichera I; Cumashi A; La Sorda R; Spinella F; Bagnato A; Lattanzio R; D'Egidio M; Di Risio A; Stampolidis P; Piantelli M; Natoli C; Ullrich A; Iacobelli S
J Mol Med (Berl); 2013 Jan; 91(1):83-94. PubMed ID: 22864925
[TBL] [Abstract][Full Text] [Related]
4. Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells.
Roforth MM; Tan C
Anticancer Drugs; 2008 Aug; 19(7):681-8. PubMed ID: 18594209
[TBL] [Abstract][Full Text] [Related]
5. 17-Allylamino-17-Demethoxygeldanamycin and the Enhancement of PS-341-Induced Lung Cancer Cell Death by Blocking the NF-κB and PI3K/Akt Pathways.
Lee KH; Jang AH; Yoo CG
Am J Respir Cell Mol Biol; 2015 Sep; 53(3):412-21. PubMed ID: 25633180
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.
Sawai A; Chandarlapaty S; Greulich H; Gonen M; Ye Q; Arteaga CL; Sellers W; Rosen N; Solit DB
Cancer Res; 2008 Jan; 68(2):589-96. PubMed ID: 18199556
[TBL] [Abstract][Full Text] [Related]
7. The HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin (17-AAG) synergizes with cisplatin and induces apoptosis in cisplatin-resistant esophageal squamous cell carcinoma cell lines via the Akt/XIAP pathway.
Ui T; Morishima K; Saito S; Sakuma Y; Fujii H; Hosoya Y; Ishikawa S; Aburatani H; Fukayama M; Niki T; Yasuda Y
Oncol Rep; 2014 Feb; 31(2):619-24. PubMed ID: 24317439
[TBL] [Abstract][Full Text] [Related]
8. Dual targeting of heat shock proteins 90 and 70 promotes cell death and enhances the anticancer effect of chemotherapeutic agents in bladder cancer.
Ma L; Sato F; Sato R; Matsubara T; Hirai K; Yamasaki M; Shin T; Shimada T; Nomura T; Mori K; Sumino Y; Mimata H
Oncol Rep; 2014 Jun; 31(6):2482-92. PubMed ID: 24718854
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol.
Solit DB; Basso AD; Olshen AB; Scher HI; Rosen N
Cancer Res; 2003 May; 63(9):2139-44. PubMed ID: 12727831
[TBL] [Abstract][Full Text] [Related]
10. Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT.
Sain N; Krishnan B; Ormerod MG; De Rienzo A; Liu WM; Kaye SB; Workman P; Jackman AL
Mol Cancer Ther; 2006 May; 5(5):1197-208. PubMed ID: 16731752
[TBL] [Abstract][Full Text] [Related]
11. 17-Allylamino-17-demethoxygeldanamycin and Herbimycin A Induce Cell Death by Modulating β-Catenin and PI3K/AKT Signaling in FRO Anaplastic Thyroid Carcinoma Cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Anticancer Res; 2015 Oct; 35(10):5453-60. PubMed ID: 26408708
[TBL] [Abstract][Full Text] [Related]
12. MEK inhibition potentiates the activity of Hsp90 inhibitor 17-AAG against pancreatic cancer cells.
Zhang T; Li Y; Zhu Z; Gu M; Newman B; Sun D
Mol Pharm; 2010 Oct; 7(5):1576-84. PubMed ID: 20669973
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of thymidine phosphorylase expression by using an HSP90 inhibitor potentiates the cytotoxic effect of cisplatin in non-small-cell lung cancer cells.
Weng SH; Tseng SC; Huang YC; Chen HJ; Lin YW
Biochem Pharmacol; 2012 Jul; 84(1):126-36. PubMed ID: 22480737
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo.
Lang SA; Klein D; Moser C; Gaumann A; Glockzin G; Dahlke MH; Dietmaier W; Bolder U; Schlitt HJ; Geissler EK; Stoeltzing O
Mol Cancer Ther; 2007 Mar; 6(3):1123-32. PubMed ID: 17363505
[TBL] [Abstract][Full Text] [Related]
15. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
Francis LK; Alsayed Y; Leleu X; Jia X; Singha UK; Anderson J; Timm M; Ngo H; Lu G; Huston A; Ehrlich LA; Dimmock E; Lentzsch S; Hideshima T; Roodman GD; Anderson KC; Ghobrial IM
Clin Cancer Res; 2006 Nov; 12(22):6826-35. PubMed ID: 17121904
[TBL] [Abstract][Full Text] [Related]
16. Acquired resistance to HSP90 inhibitor 17-AAG and increased metastatic potential are associated with MUC1 expression in colon carcinoma cells.
Liu X; Ban LL; Luo G; Li ZY; Li YF; Zhou YC; Wang XC; Jin CG; Ye JG; Ma DD; Xie Q; Huang YG
Anticancer Drugs; 2016 Jun; 27(5):417-26. PubMed ID: 26872308
[TBL] [Abstract][Full Text] [Related]
17. Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells.
Gaspar N; Sharp SY; Pacey S; Jones C; Walton M; Vassal G; Eccles S; Pearson A; Workman P
Cancer Res; 2009 Mar; 69(5):1966-75. PubMed ID: 19244114
[TBL] [Abstract][Full Text] [Related]
18. HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells.
Ko JC; Chen HJ; Huang YC; Tseng SC; Weng SH; Wo TY; Huang YJ; Chiu HC; Tsai MS; Chiou RY; Lin YW
Regul Toxicol Pharmacol; 2012 Dec; 64(3):415-24. PubMed ID: 23069143
[TBL] [Abstract][Full Text] [Related]
19. The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein-Barr virus-positive NK/T-cell lymphoma by Akt down-regulation.
Jeon YK; Park CH; Kim KY; Li YC; Kim J; Kim YA; Paik JH; Park BK; Kim CW; Kim YN
J Pathol; 2007 Oct; 213(2):170-9. PubMed ID: 17768706
[TBL] [Abstract][Full Text] [Related]
20. ATP analog enhances the actions of a heat shock protein 90 inhibitor in multiple myeloma cells.
Cervantes-Gomez F; Nimmanapalli R; Gandhi V
J Pharmacol Exp Ther; 2011 Nov; 339(2):545-54. PubMed ID: 21821695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
